Skip to content
Search

Latest Stories

Health Secretary announces £30 million fund for new technology in NHS

The Health and Social Care Secretary Steve Barclay has proposed a new £30 million fund to speed up the adoption of innovative medical technology in the NHS.

He confirmed the plan today at the Conservative Party Conference 2023 in Manchester.


Mr Barclay said that virtual wards will help healthcare professionals embrace new technology to improve patient care.

He said: “It is vital that clinicians have access to the latest technology to save staff time, deliver high-quality care and help cut waiting lists – one of the government’s top five priorities.

F7hGLfHWcAAXxkx Steve Barclay has announced a £30m medical technology plan to improve patient care. Credit: @SteveBarclay/Twitter

“This investment will see the latest tech innovations rolled out across the NHS. From virtual ward beds to wearable medical devices, patients will be better supported, and we will ease pressures on hospitals this winter.

“We’re preparing for this winter earlier than ever before including delivering thousands more hospital beds and hundreds of new ambulances.”

The announced project aims to increase productivity to tackle the NHS waiting lists and deliver improved ways to treat patients.

NHS integrated care systems (ICS) will be invited to submit bids to the Department of Health and Social Care (DHSC) and National Health Service England (NHSE) – applications are expected to open this month.

“The NHS’s world-leading ability to adopt new technology has already helped more than 210,000 patients be treated in their own homes through the rollout of virtual wards, and this new funding will allow the health service to adopt more innovations that improve patient care and reduce pressure on wider services,” said Dr Vin Diwakar, NHS interim national director of transformation.

The ICS will use the funding to expand more virtual wards where over 9,800 beds have already been created, and NHS is due to deliver 10,000 ahead of winter.

At the beginning of this year, the government published its Medical Technology Strategy that builds on £21 million of artificial intelligence spending designed to treat patients more quickly.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less